[go: up one dir, main page]

MXPA06010667A - Combinatorial methods and compositions for treatment of melanoma. - Google Patents

Combinatorial methods and compositions for treatment of melanoma.

Info

Publication number
MXPA06010667A
MXPA06010667A MXPA06010667A MXPA06010667A MXPA06010667A MX PA06010667 A MXPA06010667 A MX PA06010667A MX PA06010667 A MXPA06010667 A MX PA06010667A MX PA06010667 A MXPA06010667 A MX PA06010667A MX PA06010667 A MXPA06010667 A MX PA06010667A
Authority
MX
Mexico
Prior art keywords
melanoma
melanoma tumor
agent
treating
mammal
Prior art date
Application number
MXPA06010667A
Other languages
Spanish (es)
Inventor
Gavin P Robertson
Mark Kester
Lakshman Sandirasegarane
Arati Sharma
Original Assignee
Penn State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Penn State Res Found filed Critical Penn State Res Found
Publication of MXPA06010667A publication Critical patent/MXPA06010667A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention provides a rational basis for combining targeted therapies together with selected chemotherapeutics, which does not currently exist for the treatment of melanoma. The present invention is based on the present inventors' discovery that Akt3 regulates apoptosis and V599E B-Raf regulates growth and vascular development in melanoma. Inventors are the first to recognize an effective combined targeted therapeutic for treating melanoma. In one embodiment, the invention provides a method for inducing apoptosis in a melanoma tumor cell by reducing Akt3 activity. In yet another embodiment, the invention provides a method for inducing apoptosis in a melanoma tumor cell comprising contacting a melanoma tumor cell with an agent that reduces Akt3 activity. Consequently, the method provided restores normal apoptotic sensitivity to a melanoma tumor cell, thereby allowing the administration of a lower concentration of chemotherapeutic agents resulting in decreased toxicity to a patient. The present inventors' contemplate a method for treating a melanoma tumor in a mammal comprising: administering to a melanoma tumor an effective amount of an agent to induce apoptosis; and administering to a melanoma tumor an effective amount of an agent to reduce angiogenesis and cell proliferation. Also disclosed herein is a method for treating a melanoma in a mammal comprising: administering to a melanoma tumor in a mammal an effective amount of an agent that reduces Akt3 activity; administering to a melanoma tumor in a mammal an effective amount of an agent that reduces V599E B-Raf activity, thereby treating a melanoma tumor. In another aspect, the invention provides a pharmaceutical composition for treating a melanoma tumor comprising: an agent that reduces Akt3 activity; and a carrier.
MXPA06010667A 2004-03-19 2005-03-18 Combinatorial methods and compositions for treatment of melanoma. MXPA06010667A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55450904P 2004-03-19 2004-03-19
PCT/US2005/008950 WO2005089443A2 (en) 2004-03-19 2005-03-18 Combinatorial methods and compositions for treatment of melanoma

Publications (1)

Publication Number Publication Date
MXPA06010667A true MXPA06010667A (en) 2007-07-04

Family

ID=34994352

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06010667A MXPA06010667A (en) 2004-03-19 2005-03-18 Combinatorial methods and compositions for treatment of melanoma.

Country Status (9)

Country Link
US (4) US20050267060A1 (en)
EP (1) EP1744788A4 (en)
JP (1) JP2007530453A (en)
CN (1) CN101389345A (en)
AU (1) AU2005223649A1 (en)
BR (1) BRPI0508970A (en)
CA (1) CA2560269A1 (en)
MX (1) MXPA06010667A (en)
WO (1) WO2005089443A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
JP2002534468A (en) 1999-01-13 2002-10-15 バイエル コーポレイション ω-Carboxyaryl-substituted diphenylureas as p38 kinase inhibitors
PT1478358E (en) 2002-02-11 2013-09-11 Bayer Healthcare Llc Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis
DK1636585T3 (en) 2003-05-20 2008-05-26 Bayer Pharmaceuticals Corp Diarylurines with kinase inhibitory activity
PT1663978E (en) 2003-07-23 2008-02-15 Bayer Pharmaceuticals Corp Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
ES2400689T3 (en) 2004-10-18 2013-04-11 Amgen, Inc Thiadiazole compounds and methods of use
MX2007014920A (en) * 2005-05-27 2008-04-09 Bayer Healthcare Ag Combination therapy comprising diaryl ureas for treating diseases.
US20070178494A1 (en) * 2005-11-14 2007-08-02 James Elting Methods for prediction and prognosis of cancer, and monitoring cancer therapy
US20080306148A1 (en) 2007-04-13 2008-12-11 The Penn State Research Foundation Anti-cancer compositions and methods
WO2009011871A2 (en) 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of pkb
CA2692713A1 (en) 2007-07-17 2009-01-22 Amgen Inc. Heterocyclic modulators of pkb
KR101573026B1 (en) 2007-07-25 2015-11-30 에자이 알앤드디 매니지먼트 가부시키가이샤 Multikinase inhibitors for use in the treatment of cancer
WO2009058908A2 (en) * 2007-10-29 2009-05-07 Eisai R & D Management Co., Ltd. Methods for prognosing the ability of a zearalenone analog compound to treat cancer
US20100029657A1 (en) * 2008-02-29 2010-02-04 Wyeth Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
WO2010091354A2 (en) 2009-02-06 2010-08-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Akt tyrosine 176 phosphorylation cancer biomarker
JP5641232B2 (en) * 2010-11-24 2014-12-17 石川県公立大学法人 Ogonori-derived cyclooxygenase gene and method for producing prostaglandins using the gene
WO2012154942A2 (en) 2011-05-10 2012-11-15 The Penn State Research Foundation Ceramide anionic liposome compositions
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
WO2015041533A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
EP3526259A4 (en) * 2016-10-13 2020-06-17 Dana-Farber Cancer Institute, Inc. COMPOSITIONS AND METHODS FOR PREDICTING RESPONSE AND RESISTANCE TO CTLA4 BLOCKAGE IN MELANOMA USING GENE EXPRESSION SIGNATURE
MA50532A (en) 2017-11-03 2020-09-09 Univ Virginia Patent Foundation COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCERS
CN110476953B (en) * 2019-09-09 2021-11-12 广州中鑫基因医学科技有限公司 Cell activity preserving fluid and disease detection kit
JP2023525757A (en) * 2020-05-08 2023-06-19 ジョージアミューン・インコーポレイテッド AKT3 modulator
CN111759794B (en) * 2020-07-14 2023-07-21 中山大学 A kind of microneedle for treating melanoma and preparation method thereof
CN117110467B (en) * 2023-08-16 2024-08-20 苏州方昆医药科技有限公司 Pre-column chemical derivatization method of alcohol or phenol compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843974A (en) * 1995-06-06 1998-12-01 Eli Lilly And Company Methods of inhibiting melanoma using Benzothiophenes as cytotoxic agents per se
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US20030035790A1 (en) * 1999-01-15 2003-02-20 Shu-Hsia Chen Combination therapy for the prevention or treatment of cancer, inflammatory disorders or infectious diseases in a subject
CN1390219A (en) * 1999-09-17 2003-01-08 艾博特股份有限两合公司 Pyrazolopyrimidines as therapeutic agents
US6187586B1 (en) * 1999-12-29 2001-02-13 Isis Pharmaceuticals, Inc. Antisense modulation of AKT-3 expression
US20030004174A9 (en) * 2000-02-17 2003-01-02 Armistead David M. Kinase inhibitors
US6809194B1 (en) * 2000-05-10 2004-10-26 Chiron Corporation Akt3 inhibitors
WO2002083064A2 (en) * 2001-04-10 2002-10-24 Merck & Co., Inc. A method of treating cancer
CA2444821C (en) * 2001-04-24 2012-07-10 Merck Patent Gesellschaft Mit Beschraenkter Haftung Combination therapy using anti-angiogenic agents and tnfa
WO2003047523A2 (en) * 2001-12-04 2003-06-12 Onyx Pharmaceuticals, Inc. Raf-mek-erk pathway inhibitors to treat cancer
US6998391B2 (en) * 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
AU2003237121A1 (en) * 2002-04-26 2003-11-10 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
WO2003093430A2 (en) * 2002-05-03 2003-11-13 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for use in preparing sirnas
EP2263679B1 (en) * 2002-08-21 2014-10-08 The University Of British Columbia RNAi targeting cancer-related proteins
CA2494764C (en) * 2002-08-21 2013-04-23 The University Of British Columbia Treatment of melanoma by reduction in clusterin levels
EP2305813A3 (en) * 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
US20080161547A1 (en) * 2002-11-14 2008-07-03 Dharmacon, Inc. siRNA targeting serine/threonine protein kinase AKT
US20050221354A1 (en) * 2004-02-18 2005-10-06 Wyeth Nucleic acid arrays for monitoring expression profiles of drug target genes

Also Published As

Publication number Publication date
US20140348901A1 (en) 2014-11-27
US20130209546A1 (en) 2013-08-15
AU2005223649A1 (en) 2005-09-29
CN101389345A (en) 2009-03-18
WO2005089443A3 (en) 2009-04-23
CA2560269A1 (en) 2005-09-29
WO2005089443A2 (en) 2005-09-29
EP1744788A2 (en) 2007-01-24
US20130217949A1 (en) 2013-08-22
US20050267060A1 (en) 2005-12-01
BRPI0508970A (en) 2007-08-21
JP2007530453A (en) 2007-11-01
EP1744788A4 (en) 2010-08-18

Similar Documents

Publication Publication Date Title
MXPA06010667A (en) Combinatorial methods and compositions for treatment of melanoma.
NZ593343A (en) Combination cancer treatment conprising Abraxane and an inflamatory inhibitor
NZ605865A (en) Cns delivery of therapeutic agents
CN101001623A (en) Anticancer effect enhancer
NZ602635A (en) Methods of enhancing drug delivery and effectiveness of therapeutic agents
Cha et al. Feasibility of sorafenib combined with local radiotherapy in advanced hepatocellular carcinoma
EA200800663A1 (en) METHOD AND MEANS OF PREVENTION AND TREATMENT OF DISTURBED RESPIRATION DURING SLEEP
Lhomme et al. Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma: an EORTC Gynaecological Cancer Cooperative Group Study
EA200700214A1 (en) MEMANTINE AS AN ADDITIONAL THERAPY FOR ATYPICAL ANTIPSYCHOTIC REMEDIES IN PATIENTS WITH SCHIZOPHRENIA
MX2009004051A (en) Use of il-1 antagonists to treat gout and pseudogout.
Merenzon et al. Nitric oxide synthase inhibitors as potential therapeutic agents for gliomas: A systematic review
MX2007005581A (en) Improved dosing regimen of temozolomide for treating cancer based on the patient s mgmt level.
DE602005009176D1 (en) TREATMENT OF T-CELL LYMPHOMIC BY 10-PROPARGYL-10-DEAZAAMINEOPTERIN
Griffin et al. Preferential action of arsenic trioxide in solid-tumor microenvironment enhances radiation therapy
GB0405349D0 (en) Cancer therapy and medicaments therefor
TW200501948A (en) Composition for improving cognition and memory
WO2005009217A3 (en) Diagnosis of pre-cancerous conditions using pcdgf agents
MXPA02009984A (en) Method and composition for treating cancer by administration of apoptosis inducing chemotherapeutic agents.
Lai et al. Combined effect of topical arsenic trioxide and radiation therapy on skin-infiltrating lesions of breast cancer—a pilot study
Zustovich et al. Gemcitabine for the treatment of classic Kaposi's sarcoma: a case series
EA201270551A1 (en) TREATMENT OF NEUROTOXICITY ASSOCIATED WITH 5-FU COMBINATIONS OR HIS DRUGS WITH DPD INHIBITORS
EA200801670A1 (en) COMBINED ANTI-TRACT THERAPY WITH PERFUSION OF ISOLATED ORGAN
Bleiberg Colorectal cancer: The challenge
Nunez-Rodriguez et al. Volatile general anesthetics and oncologic surgery: A safe choice
Huang et al. Lumbar sympathetic ganglion block for cancer-associated secondary lower limb lymphedema: a retrospective study

Legal Events

Date Code Title Description
FG Grant or registration